Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects

Author(s): Russo EB

Abstract

Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene, exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study. This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol and phytol. Terpenoids share a precursor with phytocannabinoids, and are all flavour and fragrance components common to human diets that have been designated Generally Recognized as Safe by the US Food and Drug Administration and other regulatory agencies. Terpenoids are quite potent, and affect animal and even human behaviour when inhaled from ambient air at serum levels in the single digits ng·mL(-1) . They display unique therapeutic effects that may contribute meaningfully to the entourage effects of cannabis-based medicinal extracts. Particular focus will be placed on phytocannabinoid-terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin-resistant Staphylococcus aureus). Scientific evidence is presented for non-cannabinoid plant components as putative antidotes to intoxicating effects of THC that could increase its therapeutic index. Methods for investigating entourage effects in future experiments will be proposed. Phytocannabinoid-terpenoid synergy, if proven, increases the likelihood that an extensive pipeline of new therapeutic products is possible from this venerable plant. http://dx.doi.org/10.1111/bph.2011.163.issue-7.

Similar Articles

Chemotaxonomy of Cannabis I

Author(s): Beutler JA, Der Marderosian AH

Letter: Cannabinoid phenotypes in Cannabis sativa

Author(s): Small E, Beckstead HD

The inheritance of chemical phenotype in Cannabis sativa L

Author(s): de Meijer EP, Bagatta M, Carboni A, Crucitti P, Moliterni VM, et al.

Genetics and marker-assisted selection of the chemotype in Cannabis sativa L

Author(s): Pacifico D, Miselli F, Micheler M, Carboni A, Ranalli P et al

Chemical fingerprinting of cannabis as a means of source identification

Author(s): ElSohly MA, Stanford DF, Murphy TP

Metabolic fingerprinting of Cannabis sativa L

Author(s): Fischedick JT, Hazekamp A, Erkelens T, Choi YH, Verpoorte R

MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis

Author(s): Tsugawa H, Cajka T, Kind T, Ma Y, Higgins B, et al.

Chromatographic and Spectroscopic Data of Cannabinoids from Cannabis sativa L

Author(s): Hazekamp A, Peltenburg A, Verpoorte R, Giroud C

Analysis of cannabinoids in laser-microdissected trichomes of medicinal Cannabis sativa using LCMS and cryogenic NMR

Author(s): Happyana N, Agnolet S, Muntendam R, Van Dam A, Schneider B, et al.

Cannabis - from cultivar to chemovar

Author(s): Hazekamp A, Fischedick JT